30,000
Participants
Start Date
March 31, 2013
Primary Completion Date
December 31, 2033
Study Completion Date
December 31, 2035
Triple therapy
"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days"
RECRUITING
Institute of Clinical and Preventive Medicine, University of Latvia, Riga
University of Latvia
OTHER
Technion, Israel Institute of Technology
OTHER
Karolinska Institutet
OTHER
Academic Histology Laboratory (Latvia)
OTHER
Vanderbilt University
OTHER
International Agency for Research on Cancer
OTHER